Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Xiaolu Zhu, Zhao Ting, Wen-Bing Duan, Qi Chen, Jing Liu, Wen-Jing Yu, Xiaosu Zhao, Ya-Zhen Qin, Hong-Xia Shi, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2025-1671

Published: 2025

Journal Articles

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Wenbing Duan, Ying Wu, Wen-Jing Yu, Qi Chen, Zhao Ting, Jing Liu, Le-Qing Cao, Ying-Jun Chang, Xiaosu Zhao, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2025-1611

Published: 2025

Journal Articles

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Wenbing Duan, Qi Chen, Wen-Jing Yu, Xiaolu Zhu, Jing Liu, Zhao Ting, Xiaosu Zhao, Ya-Zhen Qin, Guorui Ruan, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2025-6966

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Zongru Li, Zhao Ting, Lijuan Hu, Wenbing Duan, Qian Jiang

Blood (2023) 142 (Supplement 1): 5895.

https://doi.org/10.1182/blood-2023-185471

Published: 2023

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only